Experience Of Medical Treatment With Desmopressin And Imipramine In Children With Severe Primary Nocturnal Enuresis In Taiwan
Authors Tai TT, Tai BT, Chang YJ, Huang KH
Received 1 July 2019
Accepted for publication 14 October 2019
Published 31 October 2019 Volume 2019:11 Pages 283—289
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Jan Colli
Thomson T Tai,1,2 Brent T Tai,2,3 Yu-Jun Chang,2 Kuo-Hsuan Huang4,5
1Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA; 2Department of Epidemiology and Biostatistics, Changhua Christian Hospital, Changhua, Taiwan; 3Burrell College of Osteopathic Medicine, Las Cruces, NM, USA; 4Department of Surgery, Erlin Christian Hospital, Changhua, Taiwan; 5Division of Urology, Changhua Christian Hospital, Changhua, Taiwan
Correspondence: Brent T Tai
Burrell College of Osteopathic Medicine, 3501 Arrowhead Dr, Las Cruces, NM 88001, USA
Tel +1 310 370 3757
Purpose: The aim of this study was to compare the efficacy and safety of desmopressin and imipramine in the treatment of severe primary nocturnal enuresis (NE) in Taiwan.
Patients and methods: This study was a retrospective chart review study conducted on children with primary monosymptomatic nocturnal enuresis (PMNE) or non-monosymptomatic nocturnal enuresis (PNMNE), referred to and treated by senior physicians in a Changhua medical center in Taiwan. After being screened, these children were treated with either desmopressin (n = 125) or imipramine (n = 71). All participants were treated for at least 3 months and followed afterward for at least 3 more months. The response and relapse rates were measured. Side effects were monitored. Age, gender, and severity of NE were recorded.
Results: After 3 months of treatment, 97 children treated with desmopressin were responsive (77.6%) while 58 children treated with imipramine were responsive (81.7%). Sixty-one children treated with desmopressin (48.8%) and 26 treated with imipramine (36.6%) relapsed during the 3-month post-treatment monitoring. The differences in responsive and relapse rates were not statistically significant. Four children treated with imipramine (5.6%) reported side effects while none was reported for children treated with desmopressin (P < 0.05). Age, gender, and the presence or absence of daytime enuresis did not influence the response rate to either drug (P < 0.05).
Conclusion: Currently, desmopressin is preferred over imipramine for treating NE due to the latter’s side effects. Our results demonstrated similar response rates for both drugs, with imipramine demonstrating minimal side effects. While health practitioners should pay attention to its side effects, concerns regarding imipramine toxicity in NE treatment are often overblown. Since imipramine is much cheaper than desmopressin, using imipramine to manage NE can allow health practitioners, especially in Taiwan, to treat the greatest number of children with NE.
Keywords: Taiwan, severe nocturnal enuresis, cost-effective, retrospective analysis, adverse effects, side effects
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]